Introduction
The potential role of personalized, need-based treatment strategies to improve outcomes and costs associated with hospitalization for acute heart failure (AHF) is being increasingly recognized.
1 -4 Evaluation and implementation of such strategies in daily practice demands highly accurate and objective risk stratification tools.
A multimarker risk stratification strategy based on a combination of biomarkers reflecting diverse pathophysiological pathways involved in heart failure is a promising approach that could serve as signature of disease and can greatly enhance accuracy of risk predictions. 5 -7 Although few studies reported significant prognostic improvement with multimarker panels, current data on the best combination of biomarkers for risk evaluation in AHF are inadequate. 8 -13 The latter requires a comprehensive evaluation of a broader set of biomarkers representing the multitude of pathophysiological pathways involved in heart failure. In addition, data on the timing of biomarker measurements that maximize prognostic performance of multimarker risk prediction tools are needed. In a post-hoc analysis of data from the PROTECT trial that included 48 established and novel biomarkers, we recently showed that measurements beyond hospital admission are needed for most biomarkers to attain a more optimal prognostic performance, particularly for outcome prediction after 2-3 months of the index hospitalization. 13 However, evidence on the optimal timing for repeat measurement of biomarkers during the course of hospitalization or after hospital discharge is generally lacking.
In this study, we assessed the improvement in discriminatory accuracy attained by serial evaluation of biomarkers with measurements collected beyond baseline (i.e. days 2, 5, 14, and 60) and evaluated the added prognostic value of multimarker models based on the best combination of biomarkers and time points of measurements, on top of readily available clinical and laboratory parameters.
Methods

Study population
The RELAX-AHF, a prospective, randomized, double-blind, placebo-controlled, parallel-group trial comparing serelaxin with placebo (on top of standard care) enrolled 1161 patients admitted to hospital for AHF. Patients presenting within the previous 16 h with dyspnoea at rest or with minimal exertion, pulmonary congestion on chest radiograph, BNP ≥350 ng/L or NT-proBNP ≥1400 ng/L, mild to moderate renal impairment as defined by a glomerular filtration rate of 30-75 mL/min/1.73 m 2 (estimated using the simplified Modification of Diet in Renal Disease equation), systolic blood pressure >125 mmHg, and treated with at least 40 mg of i.v. furosemide or its equivalent before screening, were included in the trial. Details of the design and main results of the study have been published previously. 14, 15 All patients provided written informed consent. The study was conducted in compliance with the Declaration of Helsinki and was approved by all relevant local ethics committees.
Study procedures and measurements
Seven circulating biomarkers [i.e. NT-proBNP, high sensitivity cardiac troponin T (hs-cTnT), cystatin-C, high sensitivity C-reactive protein (hs-CRP), soluble ST2 (sST2), galectin-3, and growth differentiation factor 15 (GDF-15)] were analysed in a central laboratory [Clinical Reference Laboratories-Europe (Fordham, Cambridgeshire, UK)] from samples collected during baseline assessment and on days 2, 5, 14, and 60. All samples from the same patient were analysed in the same batch by laboratory personnel blinded to subject treatment and study data. Hs-cTnT and NT-proBNP were measured in EDTA plasma samples using electrochemiluminescence immunoassay kits from Roche Diagnostics GmbH (Mannheim, Germany). Cystatin-C was measured in EDTA plasma using particle-enhanced turbidimetric immunoassay kits from Gentian AS (Moss, Norway). Hs-CRP was measured in serum using an immunoturbidimetric assay from Roche Diagnostics GmbH (Mannheim, Germany; Tina-quant ® C-reactive protein high sensitive assay). sST2 was measured in serum using an enzyme-linked immunoassay (ELISA) kit from Critical Diagnostics (San Diego, CA, USA; Presage ® ST2 Assay). Galectin-3 was measured in serum using an ELISA kit from BG Medicine, Inc. (Waltham, MA, USA). GDF-15 was analysed in serum samples using a pre-commercial Elecsys assay from Roche Diagnostics (Mannheim, Germany) with a reporting range of 400-40000 ng/L. The coefficient of variation (%CV) at levels of 516, 1538, and 5954 ng/L was ≤3.4%. The reporting ranges used for the other biomarkers were those defined by the assay kit manufacturer, with the exception of hs-cTnT. For hs-cTnT, the lowest value reported, defined as the lowest concentration that could be reproducibly measured with an interassay %CV <10%, was the lower limit of quantitation (LLOQ). The LLOQ and upper limit of quantitation (ULOQ) for hs-cTnT were 0.013 and 10 μg/L, respectively. The number of patients with available biomarker measurements at each evaluated time point with the corresponding number of measurements within reporting ranges are presented in the Supplementary material online, Table S1 . For our analysis, values below the LLOQ were set to 0.5 × LLOQ and values above the ULOQ were set to 1.5 × ULOQ.
Study outcome
The primary outcome evaluated in this analysis was time to cardiovascular mortality within 180 days. Vital status was recorded at all scheduled follow-up visits or contacts up to day 180, and mode of death was adjudicated centrally by a blinded endpoint committee.
Statistical analysis
All analyses were performed based on the intention-to-treat population. Continuous variables are presented as mean ± standard deviation or geometric mean with the 95% confidence interval (CI) for normally and non-normally distributed variables, respectively, while categorical variables were summarized with percentages. 2 test, Fisher's exact test, or Student's t-tests were used to compare groups as appropriate. Univariable time-dependent discriminatory accuracy of biomarker measurements from samples collected at baseline and on days 2, 5, and 14 for the prediction of cardiovascular mortality over 180 days was compared by plotting the area under the receiver operating characteristic (ROC) curve (AUC) estimated at different time points within 180 days using survival ROC analysis proposed by Heagerty et al. 16 Patients who died or were censored by day 14 (n = 27) were excluded from this analysis.
To assess the incremental predictive value of serial evaluation of biomarkers with measurements collected beyond baseline (i.e. on days 2, 5, 14, and 60), four time-dependent versions, which allowed a biomarker value to be differentially updated through the various measurement time points, were defined to represent a given biomarker effect. Version 1 utilized baseline and day 2 measurements; version 2 utilized baseline, day 2, and 5 measurements; version 3 utilized baseline, day 2, 5, and 14 measurements; and version 4 utilized further measurements at day 60 (when available), in addition to baseline, day 2, 5, and 14 measurements. The procedure for defining each version of a biomarker was implemented based on the measurement closest to the event or censoring time approach. This procedure is graphically presented in Figure 1 . The predictive values of the different versions of a biomarker were then quantified, with C-indices calculated from a time-dependent Cox proportional hazards model that included each version as a predictor. C-indices were estimated using the SAS macro 'survcstd', which calculates the C-statistics and corresponding 95% CIs for survival data with time-dependent covariates. In the next step, the C-index estimates attained by the four time-dependent versions, together with an additional version that utilized only baseline measurements, were compared. The best version of a biomarker was defined as the one that uses the fewest sets of measurement time points from among the candidate versions of the biomarker and yields a C-index within 1% of the maximum C-index attained for the biomarker under consideration. A subset of patients with available baseline measurement were included for each biomarker (see Supplementary material online, Table S1 for the number of available baseline measurements), and the last observation carried forward approach was utilized to impute for missing values in subsequent time points of biomarker measurements.
Adjusted association between an individual biomarker and outcome was assessed with a multivariable Cox proportional hazards model with a time-dependent covariate that included the best version of the biomarker and previously identified baseline predictors of 180-day cardiovascular mortality in the RELAX-AHF trial. 17 These encompassed readily available clinical variables (geographic region, systolic blood pressure, orthopnoea, angina, hyperthyroidism, mitral regurgitation, and atrial fibrillation/flutter at screening), laboratory parameters (white blood cell count, lymphocyte %, blood urea nitrogen, sodium, potassium, calcium, and total protein), and study treatment. This model showed good discriminatory performance evidenced by a C-index of 0.79 (95% CI 0.74-0.840). A stepwise selection procedure was implemented on a time-dependent Cox regression model that included the pre-defined baseline model, best version of each biomarker, and biomarker by study treatment interaction for each biomarker, to identify the best combination of biomarkers. The pre-defined baseline model was forced to stay in the model at each step of the selection procedure. Biomarkers and biomarker by study treatment interactions with P-values <0.05 were retained in the final multimarker model. Added prognostic value of individual biomarkers and combinations of biomarkers was quantified with the absolute gain in the C-index. Patients with complete baseline measurements of all candidate biomarkers (n = 1033) were included in this analysis, and missing values in subsequent moments were imputed using the last measurement carried forward approach. Moreover, missing values in variables included in the pre-specified baseline model were imputed with the treatment group-specific median (for continuous variables) or the treatment group-specific mode (for categorical variables).
Estimates are presented with 95% CIs. A P-value <0.05 was considered statistically significant. Statistical analyses were performed using SAS (version 9.4).
Results
Baseline characteristics
Around 62.4% of patients included in the intention-to-treat population were male, and mean (SD) age was 72.0 (11.2) years; 45.2% of patients had an LVEF ≥40%. Baseline clinical characteristics and laboratory values by cardiovascular death status at 180 days are presented in the Supplementary material online, Table S2 .
Biomarker measurements
A summary of levels of the seven analysed biomarkers at the different time points of measurements is provided in Table 1 . This set of biomarkers represents the main pathophysiological domains involved in heart failure including myocardial stress and injury, myocardial fibrosis and remodelling, renal function, and inflammation, among others.
Outcome
A total of 88 patients (7.6%) died from cardiovascular causes within 180 days of the index hospitalization.
Comparative analysis of predictive value of baseline, day 2, 5, and 14 measurements
Comparison of time-dependent AUCs of individual biomarkers measured from samples collected at baseline and on days 2, 5, and 14 after hospitalization indicated that day 14 measurements provide superior discriminatory accuracy for hs-CRP, GDF-15, and sST2, while baseline measurements appear to be slightly better for cystatin-C and galectin-3. Measurements beyond baseline provided clearly superior discriminatory accuracy over time for hs-cTnT and NT-proBNP, although there was no obvious difference among the day 2, 5, and 14 measurements (Supplementary material online, Figure S1 ).
Time-dependent evaluation of predictive value of biomarkers
The evaluated biomarkers showed distinctive patterns of change in predictive accuracy over the 180-day observation period, irrespective of time of measurement, as depicted in the plots of time-dependent AUCs in the Supplementary material online, Figure  S1 . hs-CRP was unique in that the predictive accuracy of a single time point measurement in the first 14 days after hospitalization showed a decreasing pattern over longer follow-up times. The other biomarkers showed a more stable discriminatory accuracy for the prediction of cardiovascular mortality over the course of the 180 days of follow-up. Values are expressed as median (interquartile range). GDF-15, growth differentiation factor 15; hs-CRP, high sensitivity C-reactive protein; hs-cTnT, high sensitivity cardiac troponin T; sST2, soluble ST2.
Incremental value of serial evaluation of individual biomarkers
The C-index estimates attained by the different versions of individual biomarkers for the prediction of 180-day cardiovascular mortality are presented in Table 2 and Figure 2 . Day 2 repeat measurement of NT-proBNP provided increment in the C-index, while subsequent measurments did not show added value. The same pattern was observed for cystatin-C, although the gain with the day 2 measurement was relatively modest. On the other hand, further evaluation of GDF-15 and hs-cTnT on day 14, in addition to day 2 or 5 measurements, provided incremental value in terms of improved discriminatory accuracy of the biomarkers. compared with day 2. For hs-CRP and sST2 (only baseline, day 14, and day 60 measurements were available for the latter), each of the subsequent measurements beyond baseline yielded a steady increment in the C-index. Galectin-3 was the only biomarker for which serial measurement did not appear to have added value over baseline measurements. GDF-15, growth differentiation factor 15; hs-CRP, high sensitivity C-reactive protein; hs-cTnT, high sensitivity cardiac troponin T; sST2, soluble ST2. The C-index and corresponding 95% confidence intervals were calculated for the different versions of a biomarker from a Cox proportional hazards model that included each version as a predictor. '-' indicates that the biomarker is not measured at this time point. GDF-15, growth differentiation factor 15; hs-CRP, high sensitivity C-reactive protein; hs-cTnT, high sensitivity cardiac troponin T; sST2, soluble ST2.
the best version of each biomarker (see the Methods for definition) ( Table 3 ). Univariable C-indices for the best versions of the biomarkers ranged from 0.64 (95% CI 0.58-0.71) for cystatin-C to 0.75 (95% CI 0.69-0.80) for hs-cTnT ( Table 2) .
Adjusted associations and added prognostic value of individual biomarkers
The baseline model-a comprehensive model that encompassed 14 known prognosticators in addition to study treatment-had a C-index of 0.79 (95% CI 0.74-0.8). Six of the seven analysed biomarkers (i.e. NT-proBNP, cystatin-C, hs-CRP, hs-cTnT, GDF-15, and sST2) were independently associated with 180-day cardiovascular mortality in multivariable Cox models that included the best version of each of the individual biomarkers and the pre-specificed baseline model and resulted in significant improvement in prognostic performance, except for cystatin-C which showed a minimal added prognostic value. The highest prognostic gain was attained with the addition of hs-cTnT, which yielded a 0.05 unit absolute increment in the C-index to 0.84 (95% CI 0.79-0.88). Individual additions of NT-proBNP, GDF-15, and sST2 to the baseline model also resulted in an ∼0.04 unit absolute gain in the C-index ( Table 3) .
Multimarker panel and added prognostic value of a combination of biomarkers
The biomarkers hs-cTnT, sST2, NT-proBNP, and GDF-15 and an interaction term between study treatment and GDF-15 were identified for inclusion in a multimarker model after implementation of a stepwise selection procedure in which the pre-defined baseline model was forced a priori. The combined addition of best versions of these biomarkers to the baseline model resulted in a 0.08 unit absolute increment in the C-index to 0.87 (95% CI 0.83-0.91). This is significantly higher than the increment in C-index attained by the addition of any of the individual biomarkers. All the four biomarkers provided significant additional prognostic information even after adjustment for each other, and variables included in the pre-defined baseline model ( 
Discussion
In this study we performed a multi-time point-based, multimarker analysis including seven established and novel biomarkers in a large, well-characterized cohort of AHF patients with significantly elevated natriuretic peptide levels and mild to moderate renal impairment. Comparative analysis of the time-dependent discriminatory accuracy of individual biomarkers indicated that measurements beyond baseline generally provide better performance for the prediction of cardiovascular mortality within 180 days. Serial measurement of biomarker values at subsequent time points beyond baseline assessment provided significant improvement in discriminatory accuracy, with the exception of galectin-3. Addition of a multi-time point-based multimarker panel, on top of readily available clinical and laboratory parameters, yielded the greatest prognostic gain. Biomarkers are the most promising risk stratification tools currently available in AHF. They serve as simple, highly objective, and relatively inexpensive tools that can significantly enhance risk prediction and stratification, and may pave the way towards need-based, personalized treatment strategies. 6,18 -20 In spite of the availability of plenty of prognostic biomarkers in AHF, clinical use remains largely limited. There are several contributing factors to this, besides the lack of evidence on the role of risk-guided, tailored treatment strategies. One of these is the fact that current biomarker-based risk prediction and stratification strategies primarily focus on single markers. This approach is suboptimal from a pathophysiological point of view since multiple pathophysiological pathways are involved in heart failure. In addition, data on optimal timing of measurements is required to maximize the prognostic utility of biomarkers. This information is very important given that levels of several biomarkers have been shown to change in parallel to treatment response. 21 -24 There are consistent data indicating that admission levels of BNP and NT-proBNP alone have limited prognostic utility. Post-hospital admission measurements of these markers, particularly pre-discharge, should be performed for better prognostication and risk stratification. 25 -29 However, evidence on timing of measurements and incremental value of serial CI, confidence interval; GDF-15, growth differentiation factor 15; HR, hazard ratio; hs-CRP, high sensitivity C-reactive protein; hs-cTnT, high sensitivity cardiac troponin T; sST2, soluble ST2. HRs should be interpreted per doubling of biomarker levels. * Only 1033 subjects with non-missing baseline data for all biomarkers are included in this analysis. Missing values in subsequent moments of measurement were imputed using the last measurement carried forward approach. The biomarkers use the best time-dependent version. 'Version' refers to the specification of the time-dependent biomarker according to the number of updated values through follow-up, starting from baseline and ending there or incorporating updated measurements through either day 2, day 5, day 14, or day 60. 'Best' refers to the version, which uses the fewest updates from among any candidate version which yields a C-index within 15 of the maximum C-index. † Adjusted for a pre-defined baseline model encompassing clinical variables (geographic region, systolic blood pressure, orthopnoea, angina, hyperthyroidism, mitral regurgitation, and atrial fibrillation/flutter at screening), laboratory parameters (white blood cell count, lymphocyte %, blood urea nitrogen, sodium, potassium, calcium, and total protein), and study treatment. The covariate orthopnoea on the ordinal scale (0,1,2,3) was dichotomized into binary as: orthopnoea: 2/3 vs. 0/1. Rationale: there were 0 subjects who died due to cardiovascular causes for orthopnoea level 'none'. ‡ Calculated using the formula (C-index for baseline model + biomarker) -(C-index for clinical model). C-index for clinical model is 0.79. CI, confidence interval; GDF-15, growth differentiation factor 15; HR, hazard ratio; hs-cTnT, high sensitivity cardiac troponin T; sST2, soluble ST2. HRs should be interpreted per doubling of biomarker levels. Note: there was a statistically significant interaction between GDF-15 and study treatment in the final multivariable model. * Adjusted for each other and 15 variables from the pre-defined baseline model including geographic region, systolic blood pressure, orthopnoea, angina, hyperthyroidism, mitral regurgitation, atrial fibrillation/flutter at screening, white blood cell count, lymphocyte %, blood urea nitrogen, sodium, potassium, calcium, total protein, and study treatment.
evaluation in AHF is highly limited for the majority of the novel biomarkers.
We utilized plots of time-dependent AUCs as a function of time to compare the discriminatory accuracy of biomarker measurements from samples collected at baseline and on days 2, 5, and 14 of the index hospitalization. In line with previous evidence, measurements beyond baseline showed better performance for NT-proBNP. 28, 29 Similarly, post-baseline measurements (particularly on day 14) provided superior discriminatory performances . for hs-CRP, hs-cTnT, GDF-15, and sST2. Cystatin-C and galectin-3 were unique in that baseline measurements were better than or at least comparable with later in-hospital and post-discharge measurements in terms of discriminatory performance. The pattern of change in AUCs over the entire follow-up time was an interesting additional observation from the plots. Most of the biomarkers showed a more stable prognostic accuracy over time irrespective of the time of measurement. However, the predictive performance of a single time point measurement of hs-CRP in the first 14 days after hospitalization showed a decreasing trend over longer follow-up times, particularly after the first 60 days of follow-up. Interestingly, these observations are highly consistent with the findings of our recent analysis of biomarkers evaluated in the PROTECT trial. 13 These findings raise an important proposition pointing towards the possibility that some markers, particularly those which change with treatment response, such as sST2, hs-CRP, and hs-cTnT, may need to be re-measured to maximize prognostic performance, while other more stable markers (e.g. galectin-3) can be measured only once. 21 -24 Subsequently, we evaluated the added value of serial evaluation of biomarker values with measurements collected during the course of hospitalization or shortly after discharge (i.e. days 2, 5, and 14) and 60 days after the index hospital admission (for some biomarkers) and assessed which time points provide incremental prognostic value. Four different patterns were seen from this analysis. Post-baseline measurements did not show added value for galectin-3. On the other hand, re-evaluation of NT-proBNP on day 2 provided significant incremental value while subsequent measurements did not show further added value. Re-evaluation of GDF-15 and hs-cTnT on day 14 yielded significant gains in discriminatory performance of the biomarkers, while each sequential measurement through day 60 showed incremental value for hs-CRP and sST2.
On the other hand, all but one (i.e. galectin-3) of the biomarkers evaluated were independently associated with cardiovascular mortality within 180 days of the index hospitalization, and five of these (i.e. NT-proBNP, hs-CRP, hs-cTnT, GDF-15, and sST2), provided added prognostic value on top of a pre-defined baseline model that included 14 readily available clinical and laboratory prognosticators, in addition to study treatment. Nevertheless, the greatest prognostic improvement was attained with the combined addition of hs-cTnT, NT-proBNP, sST2, and GDF-15. The addition of these biomarkers to the baseline model increased the C-index to 0.87, which is in the highest end of the range of model performances reported in AHF so far. 30, 31 Interestingly, all of these biomarkers provided significant additional prognostic information independent of each other in the final multimarker model. This is a further testament to the fact that several pathophysiological pathways play an important role in determining outcome in AHF patients, and no specific pathway or biomarker can adequately capture all relevant prognostic information.
Clinical implications
Evaluation of biomarkers during hospital admission is needed from a practical perspective as it can facilitate early decision-making regarding in-hospital treatment, monitoring, and even timing of discharge. However, optimal use of most biomarkers for prognostication and risk stratification requires further evaluation at later moments during hospitalization or after discharge. While a single repeat measurement of NT-proBNP as early as 48 h after initiation of in-hospital therapy or, even better, pre-discharge appears to be adequate, additional measurement of hs-cTnT and GDF-15 on day 14 (nearly a week after discharge for the typical AHF patient) may be needed to maximize predictive value. Moreover, further evaluation of hs-CRP and sST2 at 2 months after the index hospitalization, besides measurements collected during the first 2 weeks of the index hospitalization, can enhance the prognostic utility of these biomarkers in the longer term.
Furthermore, an array of pathophysiological pathways have significant independent prognostic implications in patients hospitalized with AHF. Consequently, a shift from the current single marker-based risk stratification approach to a more comprehensive strategy utilizing multimarker panels is required to optimize the utility of biomarkers for the risk stratification of AHF patients.
Future steps
Our study is only the first step towards the realization of the potential of multimarker panels as highly accurate and objective risk stratification tools in daily clinical practice. Development and external validation of a simple risk calculator that combines selected readily available clinical parameters together with a multi-time point-based multimarker panel will significantly enhance the clinical usability of the latter, and this needs to be accomplished in future studies.
Strengths and limitations
A comprehensive set of established and novel biomarkers were evaluated at multiple time points in a fairly large, well-characterized cohort of AHF patients which makes this study unique in the field.
. The results should be interpreted with some caution, however, as we performed a retrospective analysis of biomarker data collected at pre-specified time points as part of a clinical trial evaluation. Strict criteria including BNP ≥350 ng/L or NT-proBNP ≥1400 ng/L, mild to moderate renal impairment evidenced by a glomerular filtration rate of 30-75 mL/min/1.73 m 2 , and admission systolic blood pressure >125 mmHg, among others, needed to be fulfilled for inclusion in the RELAX-AHF trial. In addition, several exclusion criteria were involved in the definition of the trial patient population. These might limit the generalizability of our findings to the whole AHF patient population, and further external validation studies are needed. Moreover, patients were allowed to be included in the trial up to 16 h after presentation and were required to have received treatment with at least 40 mg of i.v furosemide or its equivalent before screening. Hence, baseline evaluation during randomization may not necessarily reflect biomarker levels at hospital admission. In addition, NT-proBNP, hs-cTnT, galectin-3, and sST2 were not evaluated at some of the measurement time points assessed. The prognostic performance of biomarkers could be influenced by LVEF status, and hence there is a possibility that selection of the best combination of biomarkers in the different LVEF-based phenotypes can, potentially, be different. Our study was, however, not adequately powered to investigate this as the number of patients and events in these subgroups were quite small, particularly for the subgroups with heart failure with preserved EF and heart failure with mid-range EF. We evaluated whether there is a significant interaction between biomarkers and LVEF status. There was a statistically significant interaction between NT-proBNP and LVEF status in univariable analysis, yet this term was not selected into the final model after implementing the stepwise selection procedure. Therefore, it is very unlikely that the best combination of biomarkers could have been influenced by LVEF status in the current study. Nonetheless, we acknowledge that this needs further investigation in adequately powered studies in the future.
Conclusion
Serial evaluation of biomarkers, beyond the time of baseline assessment, is generally needed to maximize the prognostic utility of biomarkers in AHF patients with significantly elevated natriuretic peptide levels and mild to moderate renal impairment. A combination of biomarkers reflecting diverse pathophysiological pathways provides significant prognostic improvement on top of readily available clinical and laboratory parameters unmatched by any single biomarker. Multimarker models are highly accurate and objective risk stratification tools that can play a crucial role in the development of need-based, personalized treatment strategies in AHF.
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